Rezultaty - Melpomeni Fani

Current Status of Radiopharmaceuticals for the Theranostics of Neuroendocrine Neoplasms od Melpomeni Fani, Petra Kolenc Peitl, Irina Velikyan

Connect to this object online.

Distinct In Vitro Binding Profile of the Somatostatin Receptor Subtype 2 Antagonist [¹⁷⁷Lu]Lu-OPS201 Compared to the Agonist [¹⁷⁷Lu]Lu-DOTA-TATE od Rosalba Mansi, Pascale Plas, Georges Vauquelin, Melpomeni Fani

Connect to this object online.

SPECT Imaging of SST2-Expressing Tumors with ^99mTc-Based Somatostatin Receptor Antagonists: The Role of Tetraamine, HYNIC, and Spacers od Raghuvir Haridas Gaonkar, Fabius Wiesmann, Luigi Del Pozzo, Lisa McDougall, Sandra Zanger, Renata Mikołajczak, Rosalba Mansi, Melpomeni Fani

Connect to this object online.

Development of the ^99mTc-Labelled SST₂ Antagonist TECANT-1 for a First-in-Man Multicentre Clinical Study od Doroteja Novak, Barbara Janota, Anton Amadeus Hörmann, Agnieszka Sawicka, Marko Kroselj, Alicja Hubalewska-Dydejczyk, Melpomeni Fani, Renata Mikolajczak, Petra Kolenc, Clemens Decristoforo, Piotr Garnuszek

Connect to this object online.

Selection of the First ^99mTc-Labelled Somatostatin Receptor Subtype 2 Antagonist for Clinical Translation-Preclinical Assessment of Two Optimized Candidates od Melpomeni Fani, Viktoria Weingaertner, Petra Kolenc Peitl, Rosalba Mansi, Raghuvir H. Gaonkar, Piotr Garnuszek, Renata Mikolajczak, Doroteja Novak, Urban Simoncic, Alicja Hubalewska-Dydejczyk, Christine Rangger, Piriya Kaeopookum, Clemens Decristoforo

Connect to this object online.